Cordlife Group（CLIF.F）株式概要投資持株会社であるコードライフ・グループ・リミテッドは、シンガポール、香港、インド、マレーシア、フィリピン、そして国際的に臍帯血バンクサービスを提供している。 詳細CLIF.F ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析過去5年間で収益は年間61.3%減少しました。 株式の流動性は非常に低い 意味のある時価総額がありません ( $27M )すべてのリスクチェックを見るCLIF.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW468,992 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA468,992 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$0.15138.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-11m68m2016201920222025202620282031Revenue S$18.9mEarnings S$1.4mAdvancedSet Fair ValueView all narrativesCordlife Group Limited 競合他社Concord Medical Services HoldingsSymbol: NYSE:CCMMarket cap: US$23.0mDocGoSymbol: NasdaqCM:DCGOMarket cap: US$43.0mCryo-Cell InternationalSymbol: NYSEAM:CCELMarket cap: US$36.8mLongduoduoSymbol: OTCPK:LDDDMarket cap: US$15.3m価格と性能株価の高値、安値、推移の概要Cordlife Group過去の株価現在の株価S$0.1552週高値S$0.1752週安値S$0.069ベータ0.671ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化-60.01%5年間の変化-47.14%IPOからの変化-62.38%最新ニュースお知らせ • Apr 10Cordlife Group Limited, Annual General Meeting, Apr 27, 2026Cordlife Group Limited, Annual General Meeting, Apr 27, 2026, at 09:30 Singapore Standard Time. Location: dunearn ballroom iii, raffles town club, 1 plymouth avenue, singapore 297753, Singaporeお知らせ • Jun 26Medeze Treasury Pte Ltd. completed the acquisition of 0.95% stake in Cordlife Group Limited (SGX:P8A) for SGD 0.61 million.Medeze Treasury Pte Ltd. proposed to acquire an additional 10% stake in Cordlife Group Limited (SGX:P8A) for SGD 6.4 million on May 13, 2025. A cash consideration valued at SGD 0.25 per share will be paid by Medeze Treasury Pte Ltd. As per the transaction, Medeze Treasury Pte Ltd. will acquire 25.6 million shares at SGD 0.25 per share. The transaction is subject to minimum tender and is approved by Securities Industry Council of Singapore. As of May 26, 2025, Relevant Percentage as set out under section 10.2(ii) of the Offer Announcement should be 10.07%, instead of 10.00%. assuming that as at the Record Date there is no change to the total number of Shares (excluding treasury shares), based on 256,307,744 Shares (excluding treasury shares) as at the Record Date: (i) the Relevant Number of Offer Shares to be acquired by the Offeror pursuant to the Partial Offer will be 25,630,774 Shares; and (ii) the Relevant Percentage will be approximately 10.07%. As of May 28, 2025, The Record Date of offer is 5.00 p.m. (Singapore time) on or about June 11, 2025. Despatch of Entitlement Notification Letters is on or about June 16, 2025. Closing Date in respect of the Partial Offer is 5.30 p.m. (Singapore time) on June 25, 2025 or such later date(s) as may be announced from time to time by or on behalf of Offeror. Subject to the Partial Offer becoming unconditional in all respects, settlement of the consideration for the Offer Shares acquired by the Offeror will be made within seven (7) Business Days of the Closing Date. PrimePartners Corporate Finance Pte. Ltd. served as financial advisor to Medeze Treasury Pte Ltd. Novus Corporate Finance Pte Ltd acted as independent financial adviser to directors of Cordlife Group. Medeze Treasury Pte Ltd. completed the acquisition of 0.95% stake in Cordlife Group Limited (SGX:P8A) for SGD 0.61 million on June 25, 2025.お知らせ • May 26Cordlife Group Limited, Annual General Meeting, Jun 10, 2025Cordlife Group Limited, Annual General Meeting, Jun 10, 2025, at 09:30 Singapore Standard Time. Location: dunearn ballroom iii, raffles town club, 1 plymouth avenue, singapore 297753, Singaporeお知らせ • Apr 02Cordlife Group Limited Provides Update on Testing Results for the Additional Low-Risk Tanks TestThe Board of Directors of Cordlife Group Limited refers to its announcements dated 8 April 2024 and 25 March 2025 relating to, among others, the Company sending over 200 samples of donated cord blood units ("CBUs") from the five (5) cryogenic storage tanks under investigation by the Ministry of Health which were found to be at low risk of being adversely affected by temperature excursions (" Low-Risk Tanks"), for testing across multiple third-party laboratories ("Additional Low-Risk Tanks Test"). The Board updated that it had received the full results from the Additional Low-Risk Tanks Test ("Additional Low-Risk Tanks Test Results") as of 25 March 2025. The Company is, together with its professional advisers and specialists, in the process of performing a technical analysis on the Additional Low-Risk Tanks Test Results.お知らせ • Feb 13Cordlife Group Limited Announces Resignation of CEO Ivan Yiu Pang Fai, Effective February 28, 2025Cordlife's group chief executive officer Ivan Yiu Pang Fai, 35, has tendered his resignation "to pursue other opportunities" and its board of directors has accepted his decision. His effective date of cessation will be February 28, 2025, Cordlife said in a Feb. 12 bourse filing. The group has commenced the search for a new group CEO and said it would make an "appropriate announcement" when one is appointed. He was appointed as Cordlife's group CEO around a year earlier, on February 19, 2024. The company disclosed then that his brother Yiu Ming Yiu is a non-independent, non-executive director of Cordlife. His father Yiu Chi Shing and his mother Lui Yim Sheung are deemed interested in Cordlife shares held by TransGlobal Real Estate Group, a controlling shareholder of the healthcare group. Mr. Yiu Pang Fai was formerly an executive director of TransGlobal's family office division in Hong Kong prior to his appointment as Cordlife's group CEO.お知らせ • Jan 08Cordlife Group Limited Announces Board ChangesThe Board of Directors of Cordlife Group Limited announced that: Dato' Dr. Teo Tong Kooi has informed the Board that he wished to step down as the Chairman of the Board with immediate effect. The Board records its appreciation for Dato' Dr. Teo's contributions and leadership in his tenure as Chairman. Dato' Dr. Teo will remain on the Board as an Independent Director and retain his respective roles as the Chairman of the Nominating Committee and the Remuneration Committee as well as a member of the Audit and Risk Committee. Mr. Zhai Lingyun has been redesignated from Non-Independent Non-Executive Director to Non-Independent Non-Executive Chairman with immediate effect. Consequent to the abovementioned, the composition of the Board is as follows: Mr. Zhai Lingyun-Chairman, Non-Independent Non-Executive Director; Ms. Chen Xiaoling-Group Executive Director; Mr. Yiu Ming You-Non-Independent Non-Executive Director; Mr. Chow Wai Leong-Non-Independent Non-Executive Director; Dato' Dr. Teo Tong Kooi-Independent Director; Dr. Xu, Tianhong- Independent Director; Mr. Cai, Yong-Independent Director; Mr. Gao Xiang- Independent Director; Dr. Wang Xiaorui-Independent Director; Mr. Sim Sze Kuan-Independent Director. There will be no change to the composition of the Board Committees.最新情報をもっと見るRecent updatesお知らせ • Apr 10Cordlife Group Limited, Annual General Meeting, Apr 27, 2026Cordlife Group Limited, Annual General Meeting, Apr 27, 2026, at 09:30 Singapore Standard Time. Location: dunearn ballroom iii, raffles town club, 1 plymouth avenue, singapore 297753, Singaporeお知らせ • Jun 26Medeze Treasury Pte Ltd. completed the acquisition of 0.95% stake in Cordlife Group Limited (SGX:P8A) for SGD 0.61 million.Medeze Treasury Pte Ltd. proposed to acquire an additional 10% stake in Cordlife Group Limited (SGX:P8A) for SGD 6.4 million on May 13, 2025. A cash consideration valued at SGD 0.25 per share will be paid by Medeze Treasury Pte Ltd. As per the transaction, Medeze Treasury Pte Ltd. will acquire 25.6 million shares at SGD 0.25 per share. The transaction is subject to minimum tender and is approved by Securities Industry Council of Singapore. As of May 26, 2025, Relevant Percentage as set out under section 10.2(ii) of the Offer Announcement should be 10.07%, instead of 10.00%. assuming that as at the Record Date there is no change to the total number of Shares (excluding treasury shares), based on 256,307,744 Shares (excluding treasury shares) as at the Record Date: (i) the Relevant Number of Offer Shares to be acquired by the Offeror pursuant to the Partial Offer will be 25,630,774 Shares; and (ii) the Relevant Percentage will be approximately 10.07%. As of May 28, 2025, The Record Date of offer is 5.00 p.m. (Singapore time) on or about June 11, 2025. Despatch of Entitlement Notification Letters is on or about June 16, 2025. Closing Date in respect of the Partial Offer is 5.30 p.m. (Singapore time) on June 25, 2025 or such later date(s) as may be announced from time to time by or on behalf of Offeror. Subject to the Partial Offer becoming unconditional in all respects, settlement of the consideration for the Offer Shares acquired by the Offeror will be made within seven (7) Business Days of the Closing Date. PrimePartners Corporate Finance Pte. Ltd. served as financial advisor to Medeze Treasury Pte Ltd. Novus Corporate Finance Pte Ltd acted as independent financial adviser to directors of Cordlife Group. Medeze Treasury Pte Ltd. completed the acquisition of 0.95% stake in Cordlife Group Limited (SGX:P8A) for SGD 0.61 million on June 25, 2025.お知らせ • May 26Cordlife Group Limited, Annual General Meeting, Jun 10, 2025Cordlife Group Limited, Annual General Meeting, Jun 10, 2025, at 09:30 Singapore Standard Time. Location: dunearn ballroom iii, raffles town club, 1 plymouth avenue, singapore 297753, Singaporeお知らせ • Apr 02Cordlife Group Limited Provides Update on Testing Results for the Additional Low-Risk Tanks TestThe Board of Directors of Cordlife Group Limited refers to its announcements dated 8 April 2024 and 25 March 2025 relating to, among others, the Company sending over 200 samples of donated cord blood units ("CBUs") from the five (5) cryogenic storage tanks under investigation by the Ministry of Health which were found to be at low risk of being adversely affected by temperature excursions (" Low-Risk Tanks"), for testing across multiple third-party laboratories ("Additional Low-Risk Tanks Test"). The Board updated that it had received the full results from the Additional Low-Risk Tanks Test ("Additional Low-Risk Tanks Test Results") as of 25 March 2025. The Company is, together with its professional advisers and specialists, in the process of performing a technical analysis on the Additional Low-Risk Tanks Test Results.お知らせ • Feb 13Cordlife Group Limited Announces Resignation of CEO Ivan Yiu Pang Fai, Effective February 28, 2025Cordlife's group chief executive officer Ivan Yiu Pang Fai, 35, has tendered his resignation "to pursue other opportunities" and its board of directors has accepted his decision. His effective date of cessation will be February 28, 2025, Cordlife said in a Feb. 12 bourse filing. The group has commenced the search for a new group CEO and said it would make an "appropriate announcement" when one is appointed. He was appointed as Cordlife's group CEO around a year earlier, on February 19, 2024. The company disclosed then that his brother Yiu Ming Yiu is a non-independent, non-executive director of Cordlife. His father Yiu Chi Shing and his mother Lui Yim Sheung are deemed interested in Cordlife shares held by TransGlobal Real Estate Group, a controlling shareholder of the healthcare group. Mr. Yiu Pang Fai was formerly an executive director of TransGlobal's family office division in Hong Kong prior to his appointment as Cordlife's group CEO.お知らせ • Jan 08Cordlife Group Limited Announces Board ChangesThe Board of Directors of Cordlife Group Limited announced that: Dato' Dr. Teo Tong Kooi has informed the Board that he wished to step down as the Chairman of the Board with immediate effect. The Board records its appreciation for Dato' Dr. Teo's contributions and leadership in his tenure as Chairman. Dato' Dr. Teo will remain on the Board as an Independent Director and retain his respective roles as the Chairman of the Nominating Committee and the Remuneration Committee as well as a member of the Audit and Risk Committee. Mr. Zhai Lingyun has been redesignated from Non-Independent Non-Executive Director to Non-Independent Non-Executive Chairman with immediate effect. Consequent to the abovementioned, the composition of the Board is as follows: Mr. Zhai Lingyun-Chairman, Non-Independent Non-Executive Director; Ms. Chen Xiaoling-Group Executive Director; Mr. Yiu Ming You-Non-Independent Non-Executive Director; Mr. Chow Wai Leong-Non-Independent Non-Executive Director; Dato' Dr. Teo Tong Kooi-Independent Director; Dr. Xu, Tianhong- Independent Director; Mr. Cai, Yong-Independent Director; Mr. Gao Xiang- Independent Director; Dr. Wang Xiaorui-Independent Director; Mr. Sim Sze Kuan-Independent Director. There will be no change to the composition of the Board Committees.お知らせ • Nov 15+ 3 more updatesCordlife Group Limited Appoints Gao Xiang as Independent Non-Executive Director, Effective 14 November 2024 and Chairman of Audit and Risk Committee, Effective 30 November 2024Cordlife Group Limited appointed Gao Xiang as Independent Non-Executive Director, Effective 14 November 2024 and Chairman of Audit and Risk Committee, Effective 30 November 2024. The Board, taking into consideration the academic and professional qualifications, expertise, working experience and knowledge of Mr. Gao Xiang, and is satisfied that Mr. Gao possess the requisite competencies and experience to assume the responsibilities as an Independent Non-Executive Director of the Company. Working Experience- Present Jingon Enterprise, Director (July 2024 - present) The Ugift Company Ltd, Director (January 2017 - present) Past (for the last 10 years) Chairman & CEO of Anhui Taoliwang Technology Company LTD (July 2006 -2024) Other DirectorShips Past- Chairman & CEO of Anhui Taoliwang Technology Company LTD (July 2006 -2024). Other DirectorShips Present- Jingon Enterprise, Director (July 2024 - present) The Ugift Company Ltd, Director (January 2017 - present). Director Experience Details- The Company will arrange the relevant training course on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange for Mr. Guo after his appointment. Professional Qualifications- Shanghai International Studies University - BA, Arts Columbia Business School Columbia University - MBA, Finance Cheung Kong Graduate School of Business - EMBA, Corporate Management, EMBA non-degree People's Bank of China Business School, School of Finance Qinghua University - EMBA, Finance.お知らせ • Oct 10Cordlife Group Limited Announces Change of Joint Company SecretariesCordlife Group Limited announced that Ms. Cheok Hui Yee has been appointed as the Joint Company Secretary of the Company with effect from 10 October 2024 in place of Ms. Sharon Lim Siew Choo who has resigned as the Joint Company Secretary of the Company with effect from 10 October 2024. Ms. Goh Xun Er, remains as the Company Secretary of the Company. The Board of Directors also wishes to take this opportunity to thank Ms. Sharon for her past services rendered during her tenure as the Joint Company Secretary.お知らせ • Sep 10Cordlife Group Limited Announces Cessation of Tan Huiying as Group Director, Quality and Operations, Effective 4 November 2024Cordlife Group Limited announced the cessation of Tan Huiying as Group Director, Quality and Operations. Role And Responsibilities: As Group Director, Quality and Operations, Ms Tan Huiying is responsible for the Group's operations, information systems and technology, business development activities, and ensuring the Group's quality standards in service and product offerings are maintained according to applicable standards. Reason For Cessation: Ms. Tan Huiying has informed the Company that she has resigned as Group Director, Quality and Operations to pursue her personal interests. Her last day of service will be 4 November 2024. She will relinquish all her appointments within the Group by her last day of service. Her resignation has been accepted by the board of directors of the Company.お知らせ • Jul 18Cordlife Group Limited Announces Re-Designation of Chen Xiaoling from Non-Independent Non-Executive Director to Group Executive DirectorThe Board of Directors of Cordlife Group Limited announced the re-designation of Ms. Chen Xiaoling from Non-Independent Non-Executive Director to Group Executive Director with effect from 17 July 2024. As a Group Executive Director, Ms. Chen's immediate role focuses on addressing the critical challenges currently faced by the Company during this pivotal period. Her responsibilities include identifying and prioritizing these challenges, devising strategic solutions, and ensuring timely and effective implementation. This involves closely collaborating with relevant stakeholders to mitigate risks, maintain operational stability, and support the Company's overall objectives amidst the challenges. Her efforts aim to foster resilience and steer the Company towards sustainable growth and success in the face of current difficulties. The Board of Directors comprises Dato' Dr. Teo Tong Kooi as Chairman and Independent Director (ID), Ms. Chen Xiaoling as Group Executive Director (GED), Mr. Zhai Lingyun, Mr. Yiu Ming Yiu, and Mr. Chow Wai Leong as Non-Independent Non-Executive Directors (NINED), and Mr. Cai Yong and Dr. Xu Tianhong as Independent Directors (ID). The Audit and Risk Committee consists of Mr. Cai Yong (Chairman/ID), Mr. Yiu Ming Yiu (Member/NINED), and Dato' Dr. Teo Tong Kooi (Member/ID). The Nominating Committee includes Dato' Dr. Teo Tong Kooi (Chairman/ID), Ms. Chen Xiaoling (Member/GED), Mr. Yiu Ming Yiu (Member/NINED), Mr. Cai Yong (Member/ID), and Dr. Xu Tianhong (Member/ID). The Remuneration Committee is composed of Dato' Dr. Teo Tong Kooi (Chairman/ID), Ms. Chen Xiaoling (Member/GED), Mr. Chow Wai Leong (Member/NINED), Dr. Xu Tianhong (Member/ID), and Mr. Cai Yong (Member/ID).お知らせ • May 25+ 1 more updateCordlife Group Limited Announces Changes to the Composition of Board and the Board CompositionThe Board of Directors of Cordlife Group Limited informed that, in view of the changes to the Board following the Company's annual general meeting held on 14 May 2024, the Board has undertaken a review of the composition of the Board and the committees of the Board for compliance with the Listing Manual of the Singapore Exchange Securities Trading Limited ("Listing Manual") and the Code of Corporate Governance issued by the Monetary Authority of Singapore on 6 August 2018, and the Board announced the following changes to the composition of the Board and the committees of the Board: Dato' Dr. Teo Tong Kooi ("Dato' Dr. Teo") has been appointed as Chairman of the Board with effect from 23 May 2024. He is an independent and non-executive Director ("ID"). Dato' Dr. Teo has also been appointed as Chairman of the Nominating Committee and the Remuneration Committee and a member of the Audit and Risk Committee with effect from 23 May 2024. The Board considered Dato' Dr. Teo to be independent for the purpose of Rule 704(8) of the Listing Manual. Dato' Dr. Teo has extensive experience in corporate advisory and investment management, holding key leadership positions in various multinational corporations and conglomerates, including public listed companies. Mr. Cai, Yong ("Mr. Cai"), who is currently an Independent Director of the Company, has been appointed as the Chairman of the Audit and Risk Committee and a member of the Nominating Committee and the Remuneration Committee with effect from 23 May 2024. The Board considered Mr. Cai to be independent for the purpose of Rule 704(8) of the Listing Manual. Mr. Cai has management experience in multinational corporations as well as large state-owned and private enterprises in the PRC, particularly in financial management, risk management and project management. Dr. Xu, Tianhong, who is currently an Independent Director of the Company, has been appointed as a member of the Nominating Committee and Remuneration Committee with effect from 23 May 2024. Ms. Chen Xiaoling ("Ms Chen"), who is currently a Non-Independent Non-Executive Director of the Company, has been appointed as a member of the Nominating Committee with effect from 23 May 2024. Ms Chen continues to serve as a member of the Remuneration Committee. Mr. Yiu Ming Yiu ("Mr Yiu"), who is currently a Non-Independent Non-Executive Director of the Company, has been appointed as a member of the Nominating Committee with effect from 23 May 2024. Mr. Yiu continues to serve as a member of the Audit and Risk Committee. Mr. Zhai Lingyun ("Mr Zhai"), who is currently a Non-Independent Non-Executive Director of the Company, has relinquished his role as a member of the Nominating Committee with effect from 23 May 2024. Mr. Zhai who is currently a Non-Independent Non-Executive Director of the Company, decided to relinquish his role as a member of the Nominating Committee with effect from 23 May 2024, to facilitate gradual renewal and introduce fresh perspectives on the Nominating Committee. Despite this transition, Mr. Zhai continues to serve as a Non-Independent Non-Executive Director of the Company.お知らせ • May 16Cordlife Group Limited Announces Retirement of Cheong Tuck Yan Titus Jim as Independent DirectorCordlife Group Limited announced retirement of Cheong Tuck Yan Titus Jim as Independent director. Role and Responsibilities: Independent Director, Chairman of the Audit and Risk Committee, Member of the Nominating Committee and Remuneration Committee . Job title:Independent Director, Chairman of the Audit and Risk Committee, Member of the Nominating Committee and Remuneration Committee. Other directorships present:Mercy Relief Limited (resignation submitted on 27 March 2024, pending acceptance). Reason cessation: at conclusion of the Annual General Meeting held on 14 May 2024 as Resolution 2 relating to the re-election of Mr. Cheong was not passed by Shareholders at the AGM.お知らせ • May 15+ 2 more updatesCordlife Group Limited Announces the Appointment of Dato' Dr. Teo Tong Kooi as Independent Non-Executive Director, Effective May 14, 2024Cordlife Group Limited announced the appointment of Dato' Dr. Teo Tong Kooi as Independent Non-Executive Director, effective May 14, 2024. Appointment as approved by shareholders at the annual general meeting held on 14 May 2024 pursuant to Section 183 of the Companies Act 1967 of Singapore. Working Experience: March 2018 - present: Chief Executive Officer - DPS Corporate Advisory Company Limited March 2018 - present: Independent Director - UOB Kay Hian Securities (M) Sdn Bhd March 2018 - present: Independent Director - China Automative Systems Inc. September 2014 - February 2018: Managing Director, Guoco Investment (China) Ltd., Hong Kong, and concurrently, Director/Legal Representative of Guocoland China Ltd. July 2012 - August 2014: Group Managing Director - Guocoland (China) Ltd. The Company will arrange Dato' Dr. Teo to attend the training programme conducted by a training provider as specified in Practice Note 2.3 of the Listing Manual of the Singapore Exchange Securities Trading Limited within 1 year from his appointment date. Professional Qualifications: B.Sc. in Marketing Management, Golden Gate University, San Francisco, California, USA - 1983 Master of Business Administration, Golden Gate University, San Francisco, California, USA - 1985 Stanford Executive Programme, Graduate School of Business, Stanford University, California, USA - 2002 Doctor of Professional Studies in Business, jointly offered by National School of Development, Peking University & Gabelli School of Business, New York Fordham University - 2019.お知らせ • May 11Cordlife Group Limited Announces Directors RemovalCordlife Group Limited announced removal of Ho Choon Hou, Yeo Hwee Tiong, Cheong Tuck Yan Titus Jim, Joseph Wong Wai Leung and Zhai Lingyun as a Director.お知らせ • Apr 30+ 1 more updateCordlife Group Limited Announces Board ChangesCordlife Group Limited announced that at its AGM to be held on 14 May 2024, to consider removal of Dr. Ho Choon Hou, Mr. Yeo Hwee Tiong, Mr. Cheong Tuck Yan Titus Jim as director of the company. Also announced Retirement of Mr. Joseph Wong Wai Leung as Independent Non-Executive Director. Mr. Wong has served on the Board of Directors (the "Board") for more than nine years since his appointment as Director of the Company on 23 September 2014. As part of the board renewal process, Mr. Wong has indicated to the Board of Directors that he will not be seeking for re-election at the forthcoming annual general meeting to be held on 14 May 2024 ("AGM"). He will accordingly retire as an Independent Non-Executive Director of the Company upon conclusion of the AGM and will cease as member of the Audit and Risk Committee and Remuneration Committee of the Company at the conclusion of the upcoming AGM.お知らせ • Apr 18Cordlife Group Limited has filed a Follow-on Equity Offering in the amount of SGD 8.191276 million.Cordlife Group Limited has filed a Follow-on Equity Offering in the amount of SGD 8.191276 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 51,195,478 Price\Range: SGD 0.16 Transaction Features: Subsequent Direct Listingお知らせ • Feb 29Cordlife Group Limited Announces Changes in the Composition of the Board and Board CommitteesThe Board of Directors of Cordlife Group Limited announced that Mr. Joseph Wong Wai Leung ("Mr Wong") has stepped down as the Chairman of the Board and the Chairman of the Audit and Risk Committee of the Company with effect from 28 February 2024 due to his personal family and health reasons. Following his resignation as Chairman of the Board and Chairman of the ARC, Dr Ho Choon Hou, the Vice Chairman and Non-Independent and Non-Executive Director of the Company, has been appointed as Acting Chairman of the Board with effect from 29 February 2024 until the appointment of a new Chairman of the Board; and Mr. Cheong Tuck Yan Titus Jim, the Independent Director of the Company, has been appointed as Chairman of the ARC with effect from 29 February 2024. Mr. Wong will remain as an Independent Director of the Company and a Member of the ARC andRemuneration Committee. In Audit and Risk Committee: Mr. Cheong Tuck Yan Titus Jim Chairman /Independent Director, Mr. Joseph Wong Wai Leung Member /Independent Director, Mr. Yeo Hwee Tiong Member /Independent Director, Dr Ho Choon Hou Member /NINED, Mr. Yiu Ming Yiu Member /NINED. In Nominating Committee is Mr. Yeo Hwee Tiong Chairman /Independent Director, Mr. Cheong Tuck Yan Titus Jim Member /Independent Director, Mr. Zhai Lingyun Member /NINED, In Remuneration Committee: Mr. Yeo Hwee Tiong Chairman /Independent Director Mr. Cheong Tuck Yan Titus Jim Member /Independent Director, Mr. Joseph Wong Wai Leung as Member /Independent Director. Ms Chen Xiaoling as Member /NINED, Mr. Chow Wai Leong as Member /NINED.お知らせ • Feb 20+ 1 more updateCordlife Group Limited Announces the Cessation of Tan Poh Lan as Executive DirectorThe Board of Directors of Cordlife Group Limited announced that Ms Tan Poh Lan has agreed that the effective date of cessation of her appointment as the Executive Director of the Company shall take effect on 19 February 2024.お知らせ • Oct 28+ 1 more updateCordlife Group Limited Announces Resignation of Ms. Tan Poh Lan as a Group Chief Executive Officer, Effective 31 March 2024Cordlife Group Limited announced resignation of Ms. Tan Poh Lan as a Group Chief Executive Officer (the "Group CEO") as she is retiring to pursue her personal interests. Her last day of service will be 31 March 2024. She will relinquish all her appointments within the Group by her last day of service. Her resignation as Executive Director and the Group CEO has been accepted by the board of directors of the Company.お知らせ • Jul 01Cordlife Group Limited Announces Change of Company SecretaryThe Board of Directors (the "Board") of Cordlife Group Limited announced the appointment of Ms. Low Mei Wan (Ms. Low) as Company Secretary of the company in place of Ms. Ang Siew Koon (Ms. Ang), with effect from 30 June 2023.お知らせ • May 24Cordlife Group Limited Announces Resignation of Kuan Yoke Kay as the Joint Company SecretaryThe board of directors of Cordlife Group Limited announced the resignation of Ms. Kuan Yoke Kay (Ms. Kuan) as the joint company secretary with effect from 23 May 2023. Ms. Ang Siew Koon will remain the sole company secretary.お知らせ • Jan 17Cordlife Group Limited Appoints that Hnin Yi as Group Chief Financial OfficerCordlife Group Limited appointed that Hnin Yi as Group Chief Financial Officer. Role And Responsibilities: Executive; Overall management of the Financials of the Group and help the Group achieve its objectives. Working Experience 1. Cordlife Group Limited (Jul 2010 to Jul 2013) - Financial Controller 2. Cordlife Group Limited (Aug 2013 to Jan 2017) - Chief Financial Officer 3. Cordlife Group Limited (Feb 2017 to Oct 2022) - Group Finance Director 4. Cordlife Group Limited (November 2022 to current) - Interim Group Chief Financial Officer. Professional Qualifications 1. Master of Business Administration - University of Manchester 2. Diploma in Accountancy - Ngee Ann Polytechnic.株主還元CLIF.FUS HealthcareUS 市場7D0%0.2%-1.2%1Yn/a24.1%18.3%株主還元を見る業界別リターン: CLIF.FがUS Healthcare業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: CLIF.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is CLIF.F's price volatile compared to industry and market?CLIF.F volatilityCLIF.F Average Weekly Movementn/aHealthcare Industry Average Movement7.5%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: CLIF.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のCLIF.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2001n/aShally Chenwww.cordlife.comコードライフ・グループ・リミテッドは投資持株会社で、シンガポール、香港、インド、マレーシア、フィリピン、そして国際的に臍帯血バンクサービスを提供している。バンキング事業と診断事業の2つの分野で事業を展開している。バンキング事業では、臍帯血、ライニング、組織サンプルなどの生物学的材料の収集、加工、バンク、検査を行っている。診断事業では、新生児遺伝子・代謝検査、小児視力・耳検査、小児アレルゲン検査、遺伝子タレント検査などの診断検査サービスを提供している。また、成人向けには角膜レンチキュールバンキング、腸内マイクロバイオームバンキング、生活習慣病遺伝子スクリーニングサービスを提供している。さらに、子育てリソースを提供するモバイルアプリケーション「マムズアップ」や、健康、ウェルネス、ライフスタイルのニーズに対応した新芽も提供している。さらに、医療ラボ、マーケティング、不動産投資サービス、医療・医薬研究開発、コンサルティングサービスも提供している。コードライフ・グループ・リミテッドは2001年に設立され、シンガポールを拠点としている。もっと見るCordlife Group Limited 基礎のまとめCordlife Group の収益と売上を時価総額と比較するとどうか。CLIF.F 基礎統計学時価総額US$26.65m収益（TTM）-US$8.42m売上高(TTM)US$29.11m0.9xP/Sレシオ-3.2xPER（株価収益率CLIF.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CLIF.F 損益計算書（TTM）収益S$36.96m売上原価S$15.43m売上総利益S$21.53mその他の費用S$32.22m収益-S$10.69m直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）-0.042グロス・マージン58.25%純利益率-28.93%有利子負債／自己資本比率0%CLIF.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/24 15:23終値2026/06/09 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cordlife Group Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Conrad WernerMacquarie ResearchJohn CheongMaybank Research Pte. Ltd.Derrick HengPhillip Securities (HK)1 その他のアナリストを表示
お知らせ • Apr 10Cordlife Group Limited, Annual General Meeting, Apr 27, 2026Cordlife Group Limited, Annual General Meeting, Apr 27, 2026, at 09:30 Singapore Standard Time. Location: dunearn ballroom iii, raffles town club, 1 plymouth avenue, singapore 297753, Singapore
お知らせ • Jun 26Medeze Treasury Pte Ltd. completed the acquisition of 0.95% stake in Cordlife Group Limited (SGX:P8A) for SGD 0.61 million.Medeze Treasury Pte Ltd. proposed to acquire an additional 10% stake in Cordlife Group Limited (SGX:P8A) for SGD 6.4 million on May 13, 2025. A cash consideration valued at SGD 0.25 per share will be paid by Medeze Treasury Pte Ltd. As per the transaction, Medeze Treasury Pte Ltd. will acquire 25.6 million shares at SGD 0.25 per share. The transaction is subject to minimum tender and is approved by Securities Industry Council of Singapore. As of May 26, 2025, Relevant Percentage as set out under section 10.2(ii) of the Offer Announcement should be 10.07%, instead of 10.00%. assuming that as at the Record Date there is no change to the total number of Shares (excluding treasury shares), based on 256,307,744 Shares (excluding treasury shares) as at the Record Date: (i) the Relevant Number of Offer Shares to be acquired by the Offeror pursuant to the Partial Offer will be 25,630,774 Shares; and (ii) the Relevant Percentage will be approximately 10.07%. As of May 28, 2025, The Record Date of offer is 5.00 p.m. (Singapore time) on or about June 11, 2025. Despatch of Entitlement Notification Letters is on or about June 16, 2025. Closing Date in respect of the Partial Offer is 5.30 p.m. (Singapore time) on June 25, 2025 or such later date(s) as may be announced from time to time by or on behalf of Offeror. Subject to the Partial Offer becoming unconditional in all respects, settlement of the consideration for the Offer Shares acquired by the Offeror will be made within seven (7) Business Days of the Closing Date. PrimePartners Corporate Finance Pte. Ltd. served as financial advisor to Medeze Treasury Pte Ltd. Novus Corporate Finance Pte Ltd acted as independent financial adviser to directors of Cordlife Group. Medeze Treasury Pte Ltd. completed the acquisition of 0.95% stake in Cordlife Group Limited (SGX:P8A) for SGD 0.61 million on June 25, 2025.
お知らせ • May 26Cordlife Group Limited, Annual General Meeting, Jun 10, 2025Cordlife Group Limited, Annual General Meeting, Jun 10, 2025, at 09:30 Singapore Standard Time. Location: dunearn ballroom iii, raffles town club, 1 plymouth avenue, singapore 297753, Singapore
お知らせ • Apr 02Cordlife Group Limited Provides Update on Testing Results for the Additional Low-Risk Tanks TestThe Board of Directors of Cordlife Group Limited refers to its announcements dated 8 April 2024 and 25 March 2025 relating to, among others, the Company sending over 200 samples of donated cord blood units ("CBUs") from the five (5) cryogenic storage tanks under investigation by the Ministry of Health which were found to be at low risk of being adversely affected by temperature excursions (" Low-Risk Tanks"), for testing across multiple third-party laboratories ("Additional Low-Risk Tanks Test"). The Board updated that it had received the full results from the Additional Low-Risk Tanks Test ("Additional Low-Risk Tanks Test Results") as of 25 March 2025. The Company is, together with its professional advisers and specialists, in the process of performing a technical analysis on the Additional Low-Risk Tanks Test Results.
お知らせ • Feb 13Cordlife Group Limited Announces Resignation of CEO Ivan Yiu Pang Fai, Effective February 28, 2025Cordlife's group chief executive officer Ivan Yiu Pang Fai, 35, has tendered his resignation "to pursue other opportunities" and its board of directors has accepted his decision. His effective date of cessation will be February 28, 2025, Cordlife said in a Feb. 12 bourse filing. The group has commenced the search for a new group CEO and said it would make an "appropriate announcement" when one is appointed. He was appointed as Cordlife's group CEO around a year earlier, on February 19, 2024. The company disclosed then that his brother Yiu Ming Yiu is a non-independent, non-executive director of Cordlife. His father Yiu Chi Shing and his mother Lui Yim Sheung are deemed interested in Cordlife shares held by TransGlobal Real Estate Group, a controlling shareholder of the healthcare group. Mr. Yiu Pang Fai was formerly an executive director of TransGlobal's family office division in Hong Kong prior to his appointment as Cordlife's group CEO.
お知らせ • Jan 08Cordlife Group Limited Announces Board ChangesThe Board of Directors of Cordlife Group Limited announced that: Dato' Dr. Teo Tong Kooi has informed the Board that he wished to step down as the Chairman of the Board with immediate effect. The Board records its appreciation for Dato' Dr. Teo's contributions and leadership in his tenure as Chairman. Dato' Dr. Teo will remain on the Board as an Independent Director and retain his respective roles as the Chairman of the Nominating Committee and the Remuneration Committee as well as a member of the Audit and Risk Committee. Mr. Zhai Lingyun has been redesignated from Non-Independent Non-Executive Director to Non-Independent Non-Executive Chairman with immediate effect. Consequent to the abovementioned, the composition of the Board is as follows: Mr. Zhai Lingyun-Chairman, Non-Independent Non-Executive Director; Ms. Chen Xiaoling-Group Executive Director; Mr. Yiu Ming You-Non-Independent Non-Executive Director; Mr. Chow Wai Leong-Non-Independent Non-Executive Director; Dato' Dr. Teo Tong Kooi-Independent Director; Dr. Xu, Tianhong- Independent Director; Mr. Cai, Yong-Independent Director; Mr. Gao Xiang- Independent Director; Dr. Wang Xiaorui-Independent Director; Mr. Sim Sze Kuan-Independent Director. There will be no change to the composition of the Board Committees.
お知らせ • Apr 10Cordlife Group Limited, Annual General Meeting, Apr 27, 2026Cordlife Group Limited, Annual General Meeting, Apr 27, 2026, at 09:30 Singapore Standard Time. Location: dunearn ballroom iii, raffles town club, 1 plymouth avenue, singapore 297753, Singapore
お知らせ • Jun 26Medeze Treasury Pte Ltd. completed the acquisition of 0.95% stake in Cordlife Group Limited (SGX:P8A) for SGD 0.61 million.Medeze Treasury Pte Ltd. proposed to acquire an additional 10% stake in Cordlife Group Limited (SGX:P8A) for SGD 6.4 million on May 13, 2025. A cash consideration valued at SGD 0.25 per share will be paid by Medeze Treasury Pte Ltd. As per the transaction, Medeze Treasury Pte Ltd. will acquire 25.6 million shares at SGD 0.25 per share. The transaction is subject to minimum tender and is approved by Securities Industry Council of Singapore. As of May 26, 2025, Relevant Percentage as set out under section 10.2(ii) of the Offer Announcement should be 10.07%, instead of 10.00%. assuming that as at the Record Date there is no change to the total number of Shares (excluding treasury shares), based on 256,307,744 Shares (excluding treasury shares) as at the Record Date: (i) the Relevant Number of Offer Shares to be acquired by the Offeror pursuant to the Partial Offer will be 25,630,774 Shares; and (ii) the Relevant Percentage will be approximately 10.07%. As of May 28, 2025, The Record Date of offer is 5.00 p.m. (Singapore time) on or about June 11, 2025. Despatch of Entitlement Notification Letters is on or about June 16, 2025. Closing Date in respect of the Partial Offer is 5.30 p.m. (Singapore time) on June 25, 2025 or such later date(s) as may be announced from time to time by or on behalf of Offeror. Subject to the Partial Offer becoming unconditional in all respects, settlement of the consideration for the Offer Shares acquired by the Offeror will be made within seven (7) Business Days of the Closing Date. PrimePartners Corporate Finance Pte. Ltd. served as financial advisor to Medeze Treasury Pte Ltd. Novus Corporate Finance Pte Ltd acted as independent financial adviser to directors of Cordlife Group. Medeze Treasury Pte Ltd. completed the acquisition of 0.95% stake in Cordlife Group Limited (SGX:P8A) for SGD 0.61 million on June 25, 2025.
お知らせ • May 26Cordlife Group Limited, Annual General Meeting, Jun 10, 2025Cordlife Group Limited, Annual General Meeting, Jun 10, 2025, at 09:30 Singapore Standard Time. Location: dunearn ballroom iii, raffles town club, 1 plymouth avenue, singapore 297753, Singapore
お知らせ • Apr 02Cordlife Group Limited Provides Update on Testing Results for the Additional Low-Risk Tanks TestThe Board of Directors of Cordlife Group Limited refers to its announcements dated 8 April 2024 and 25 March 2025 relating to, among others, the Company sending over 200 samples of donated cord blood units ("CBUs") from the five (5) cryogenic storage tanks under investigation by the Ministry of Health which were found to be at low risk of being adversely affected by temperature excursions (" Low-Risk Tanks"), for testing across multiple third-party laboratories ("Additional Low-Risk Tanks Test"). The Board updated that it had received the full results from the Additional Low-Risk Tanks Test ("Additional Low-Risk Tanks Test Results") as of 25 March 2025. The Company is, together with its professional advisers and specialists, in the process of performing a technical analysis on the Additional Low-Risk Tanks Test Results.
お知らせ • Feb 13Cordlife Group Limited Announces Resignation of CEO Ivan Yiu Pang Fai, Effective February 28, 2025Cordlife's group chief executive officer Ivan Yiu Pang Fai, 35, has tendered his resignation "to pursue other opportunities" and its board of directors has accepted his decision. His effective date of cessation will be February 28, 2025, Cordlife said in a Feb. 12 bourse filing. The group has commenced the search for a new group CEO and said it would make an "appropriate announcement" when one is appointed. He was appointed as Cordlife's group CEO around a year earlier, on February 19, 2024. The company disclosed then that his brother Yiu Ming Yiu is a non-independent, non-executive director of Cordlife. His father Yiu Chi Shing and his mother Lui Yim Sheung are deemed interested in Cordlife shares held by TransGlobal Real Estate Group, a controlling shareholder of the healthcare group. Mr. Yiu Pang Fai was formerly an executive director of TransGlobal's family office division in Hong Kong prior to his appointment as Cordlife's group CEO.
お知らせ • Jan 08Cordlife Group Limited Announces Board ChangesThe Board of Directors of Cordlife Group Limited announced that: Dato' Dr. Teo Tong Kooi has informed the Board that he wished to step down as the Chairman of the Board with immediate effect. The Board records its appreciation for Dato' Dr. Teo's contributions and leadership in his tenure as Chairman. Dato' Dr. Teo will remain on the Board as an Independent Director and retain his respective roles as the Chairman of the Nominating Committee and the Remuneration Committee as well as a member of the Audit and Risk Committee. Mr. Zhai Lingyun has been redesignated from Non-Independent Non-Executive Director to Non-Independent Non-Executive Chairman with immediate effect. Consequent to the abovementioned, the composition of the Board is as follows: Mr. Zhai Lingyun-Chairman, Non-Independent Non-Executive Director; Ms. Chen Xiaoling-Group Executive Director; Mr. Yiu Ming You-Non-Independent Non-Executive Director; Mr. Chow Wai Leong-Non-Independent Non-Executive Director; Dato' Dr. Teo Tong Kooi-Independent Director; Dr. Xu, Tianhong- Independent Director; Mr. Cai, Yong-Independent Director; Mr. Gao Xiang- Independent Director; Dr. Wang Xiaorui-Independent Director; Mr. Sim Sze Kuan-Independent Director. There will be no change to the composition of the Board Committees.
お知らせ • Nov 15+ 3 more updatesCordlife Group Limited Appoints Gao Xiang as Independent Non-Executive Director, Effective 14 November 2024 and Chairman of Audit and Risk Committee, Effective 30 November 2024Cordlife Group Limited appointed Gao Xiang as Independent Non-Executive Director, Effective 14 November 2024 and Chairman of Audit and Risk Committee, Effective 30 November 2024. The Board, taking into consideration the academic and professional qualifications, expertise, working experience and knowledge of Mr. Gao Xiang, and is satisfied that Mr. Gao possess the requisite competencies and experience to assume the responsibilities as an Independent Non-Executive Director of the Company. Working Experience- Present Jingon Enterprise, Director (July 2024 - present) The Ugift Company Ltd, Director (January 2017 - present) Past (for the last 10 years) Chairman & CEO of Anhui Taoliwang Technology Company LTD (July 2006 -2024) Other DirectorShips Past- Chairman & CEO of Anhui Taoliwang Technology Company LTD (July 2006 -2024). Other DirectorShips Present- Jingon Enterprise, Director (July 2024 - present) The Ugift Company Ltd, Director (January 2017 - present). Director Experience Details- The Company will arrange the relevant training course on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange for Mr. Guo after his appointment. Professional Qualifications- Shanghai International Studies University - BA, Arts Columbia Business School Columbia University - MBA, Finance Cheung Kong Graduate School of Business - EMBA, Corporate Management, EMBA non-degree People's Bank of China Business School, School of Finance Qinghua University - EMBA, Finance.
お知らせ • Oct 10Cordlife Group Limited Announces Change of Joint Company SecretariesCordlife Group Limited announced that Ms. Cheok Hui Yee has been appointed as the Joint Company Secretary of the Company with effect from 10 October 2024 in place of Ms. Sharon Lim Siew Choo who has resigned as the Joint Company Secretary of the Company with effect from 10 October 2024. Ms. Goh Xun Er, remains as the Company Secretary of the Company. The Board of Directors also wishes to take this opportunity to thank Ms. Sharon for her past services rendered during her tenure as the Joint Company Secretary.
お知らせ • Sep 10Cordlife Group Limited Announces Cessation of Tan Huiying as Group Director, Quality and Operations, Effective 4 November 2024Cordlife Group Limited announced the cessation of Tan Huiying as Group Director, Quality and Operations. Role And Responsibilities: As Group Director, Quality and Operations, Ms Tan Huiying is responsible for the Group's operations, information systems and technology, business development activities, and ensuring the Group's quality standards in service and product offerings are maintained according to applicable standards. Reason For Cessation: Ms. Tan Huiying has informed the Company that she has resigned as Group Director, Quality and Operations to pursue her personal interests. Her last day of service will be 4 November 2024. She will relinquish all her appointments within the Group by her last day of service. Her resignation has been accepted by the board of directors of the Company.
お知らせ • Jul 18Cordlife Group Limited Announces Re-Designation of Chen Xiaoling from Non-Independent Non-Executive Director to Group Executive DirectorThe Board of Directors of Cordlife Group Limited announced the re-designation of Ms. Chen Xiaoling from Non-Independent Non-Executive Director to Group Executive Director with effect from 17 July 2024. As a Group Executive Director, Ms. Chen's immediate role focuses on addressing the critical challenges currently faced by the Company during this pivotal period. Her responsibilities include identifying and prioritizing these challenges, devising strategic solutions, and ensuring timely and effective implementation. This involves closely collaborating with relevant stakeholders to mitigate risks, maintain operational stability, and support the Company's overall objectives amidst the challenges. Her efforts aim to foster resilience and steer the Company towards sustainable growth and success in the face of current difficulties. The Board of Directors comprises Dato' Dr. Teo Tong Kooi as Chairman and Independent Director (ID), Ms. Chen Xiaoling as Group Executive Director (GED), Mr. Zhai Lingyun, Mr. Yiu Ming Yiu, and Mr. Chow Wai Leong as Non-Independent Non-Executive Directors (NINED), and Mr. Cai Yong and Dr. Xu Tianhong as Independent Directors (ID). The Audit and Risk Committee consists of Mr. Cai Yong (Chairman/ID), Mr. Yiu Ming Yiu (Member/NINED), and Dato' Dr. Teo Tong Kooi (Member/ID). The Nominating Committee includes Dato' Dr. Teo Tong Kooi (Chairman/ID), Ms. Chen Xiaoling (Member/GED), Mr. Yiu Ming Yiu (Member/NINED), Mr. Cai Yong (Member/ID), and Dr. Xu Tianhong (Member/ID). The Remuneration Committee is composed of Dato' Dr. Teo Tong Kooi (Chairman/ID), Ms. Chen Xiaoling (Member/GED), Mr. Chow Wai Leong (Member/NINED), Dr. Xu Tianhong (Member/ID), and Mr. Cai Yong (Member/ID).
お知らせ • May 25+ 1 more updateCordlife Group Limited Announces Changes to the Composition of Board and the Board CompositionThe Board of Directors of Cordlife Group Limited informed that, in view of the changes to the Board following the Company's annual general meeting held on 14 May 2024, the Board has undertaken a review of the composition of the Board and the committees of the Board for compliance with the Listing Manual of the Singapore Exchange Securities Trading Limited ("Listing Manual") and the Code of Corporate Governance issued by the Monetary Authority of Singapore on 6 August 2018, and the Board announced the following changes to the composition of the Board and the committees of the Board: Dato' Dr. Teo Tong Kooi ("Dato' Dr. Teo") has been appointed as Chairman of the Board with effect from 23 May 2024. He is an independent and non-executive Director ("ID"). Dato' Dr. Teo has also been appointed as Chairman of the Nominating Committee and the Remuneration Committee and a member of the Audit and Risk Committee with effect from 23 May 2024. The Board considered Dato' Dr. Teo to be independent for the purpose of Rule 704(8) of the Listing Manual. Dato' Dr. Teo has extensive experience in corporate advisory and investment management, holding key leadership positions in various multinational corporations and conglomerates, including public listed companies. Mr. Cai, Yong ("Mr. Cai"), who is currently an Independent Director of the Company, has been appointed as the Chairman of the Audit and Risk Committee and a member of the Nominating Committee and the Remuneration Committee with effect from 23 May 2024. The Board considered Mr. Cai to be independent for the purpose of Rule 704(8) of the Listing Manual. Mr. Cai has management experience in multinational corporations as well as large state-owned and private enterprises in the PRC, particularly in financial management, risk management and project management. Dr. Xu, Tianhong, who is currently an Independent Director of the Company, has been appointed as a member of the Nominating Committee and Remuneration Committee with effect from 23 May 2024. Ms. Chen Xiaoling ("Ms Chen"), who is currently a Non-Independent Non-Executive Director of the Company, has been appointed as a member of the Nominating Committee with effect from 23 May 2024. Ms Chen continues to serve as a member of the Remuneration Committee. Mr. Yiu Ming Yiu ("Mr Yiu"), who is currently a Non-Independent Non-Executive Director of the Company, has been appointed as a member of the Nominating Committee with effect from 23 May 2024. Mr. Yiu continues to serve as a member of the Audit and Risk Committee. Mr. Zhai Lingyun ("Mr Zhai"), who is currently a Non-Independent Non-Executive Director of the Company, has relinquished his role as a member of the Nominating Committee with effect from 23 May 2024. Mr. Zhai who is currently a Non-Independent Non-Executive Director of the Company, decided to relinquish his role as a member of the Nominating Committee with effect from 23 May 2024, to facilitate gradual renewal and introduce fresh perspectives on the Nominating Committee. Despite this transition, Mr. Zhai continues to serve as a Non-Independent Non-Executive Director of the Company.
お知らせ • May 16Cordlife Group Limited Announces Retirement of Cheong Tuck Yan Titus Jim as Independent DirectorCordlife Group Limited announced retirement of Cheong Tuck Yan Titus Jim as Independent director. Role and Responsibilities: Independent Director, Chairman of the Audit and Risk Committee, Member of the Nominating Committee and Remuneration Committee . Job title:Independent Director, Chairman of the Audit and Risk Committee, Member of the Nominating Committee and Remuneration Committee. Other directorships present:Mercy Relief Limited (resignation submitted on 27 March 2024, pending acceptance). Reason cessation: at conclusion of the Annual General Meeting held on 14 May 2024 as Resolution 2 relating to the re-election of Mr. Cheong was not passed by Shareholders at the AGM.
お知らせ • May 15+ 2 more updatesCordlife Group Limited Announces the Appointment of Dato' Dr. Teo Tong Kooi as Independent Non-Executive Director, Effective May 14, 2024Cordlife Group Limited announced the appointment of Dato' Dr. Teo Tong Kooi as Independent Non-Executive Director, effective May 14, 2024. Appointment as approved by shareholders at the annual general meeting held on 14 May 2024 pursuant to Section 183 of the Companies Act 1967 of Singapore. Working Experience: March 2018 - present: Chief Executive Officer - DPS Corporate Advisory Company Limited March 2018 - present: Independent Director - UOB Kay Hian Securities (M) Sdn Bhd March 2018 - present: Independent Director - China Automative Systems Inc. September 2014 - February 2018: Managing Director, Guoco Investment (China) Ltd., Hong Kong, and concurrently, Director/Legal Representative of Guocoland China Ltd. July 2012 - August 2014: Group Managing Director - Guocoland (China) Ltd. The Company will arrange Dato' Dr. Teo to attend the training programme conducted by a training provider as specified in Practice Note 2.3 of the Listing Manual of the Singapore Exchange Securities Trading Limited within 1 year from his appointment date. Professional Qualifications: B.Sc. in Marketing Management, Golden Gate University, San Francisco, California, USA - 1983 Master of Business Administration, Golden Gate University, San Francisco, California, USA - 1985 Stanford Executive Programme, Graduate School of Business, Stanford University, California, USA - 2002 Doctor of Professional Studies in Business, jointly offered by National School of Development, Peking University & Gabelli School of Business, New York Fordham University - 2019.
お知らせ • May 11Cordlife Group Limited Announces Directors RemovalCordlife Group Limited announced removal of Ho Choon Hou, Yeo Hwee Tiong, Cheong Tuck Yan Titus Jim, Joseph Wong Wai Leung and Zhai Lingyun as a Director.
お知らせ • Apr 30+ 1 more updateCordlife Group Limited Announces Board ChangesCordlife Group Limited announced that at its AGM to be held on 14 May 2024, to consider removal of Dr. Ho Choon Hou, Mr. Yeo Hwee Tiong, Mr. Cheong Tuck Yan Titus Jim as director of the company. Also announced Retirement of Mr. Joseph Wong Wai Leung as Independent Non-Executive Director. Mr. Wong has served on the Board of Directors (the "Board") for more than nine years since his appointment as Director of the Company on 23 September 2014. As part of the board renewal process, Mr. Wong has indicated to the Board of Directors that he will not be seeking for re-election at the forthcoming annual general meeting to be held on 14 May 2024 ("AGM"). He will accordingly retire as an Independent Non-Executive Director of the Company upon conclusion of the AGM and will cease as member of the Audit and Risk Committee and Remuneration Committee of the Company at the conclusion of the upcoming AGM.
お知らせ • Apr 18Cordlife Group Limited has filed a Follow-on Equity Offering in the amount of SGD 8.191276 million.Cordlife Group Limited has filed a Follow-on Equity Offering in the amount of SGD 8.191276 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 51,195,478 Price\Range: SGD 0.16 Transaction Features: Subsequent Direct Listing
お知らせ • Feb 29Cordlife Group Limited Announces Changes in the Composition of the Board and Board CommitteesThe Board of Directors of Cordlife Group Limited announced that Mr. Joseph Wong Wai Leung ("Mr Wong") has stepped down as the Chairman of the Board and the Chairman of the Audit and Risk Committee of the Company with effect from 28 February 2024 due to his personal family and health reasons. Following his resignation as Chairman of the Board and Chairman of the ARC, Dr Ho Choon Hou, the Vice Chairman and Non-Independent and Non-Executive Director of the Company, has been appointed as Acting Chairman of the Board with effect from 29 February 2024 until the appointment of a new Chairman of the Board; and Mr. Cheong Tuck Yan Titus Jim, the Independent Director of the Company, has been appointed as Chairman of the ARC with effect from 29 February 2024. Mr. Wong will remain as an Independent Director of the Company and a Member of the ARC andRemuneration Committee. In Audit and Risk Committee: Mr. Cheong Tuck Yan Titus Jim Chairman /Independent Director, Mr. Joseph Wong Wai Leung Member /Independent Director, Mr. Yeo Hwee Tiong Member /Independent Director, Dr Ho Choon Hou Member /NINED, Mr. Yiu Ming Yiu Member /NINED. In Nominating Committee is Mr. Yeo Hwee Tiong Chairman /Independent Director, Mr. Cheong Tuck Yan Titus Jim Member /Independent Director, Mr. Zhai Lingyun Member /NINED, In Remuneration Committee: Mr. Yeo Hwee Tiong Chairman /Independent Director Mr. Cheong Tuck Yan Titus Jim Member /Independent Director, Mr. Joseph Wong Wai Leung as Member /Independent Director. Ms Chen Xiaoling as Member /NINED, Mr. Chow Wai Leong as Member /NINED.
お知らせ • Feb 20+ 1 more updateCordlife Group Limited Announces the Cessation of Tan Poh Lan as Executive DirectorThe Board of Directors of Cordlife Group Limited announced that Ms Tan Poh Lan has agreed that the effective date of cessation of her appointment as the Executive Director of the Company shall take effect on 19 February 2024.
お知らせ • Oct 28+ 1 more updateCordlife Group Limited Announces Resignation of Ms. Tan Poh Lan as a Group Chief Executive Officer, Effective 31 March 2024Cordlife Group Limited announced resignation of Ms. Tan Poh Lan as a Group Chief Executive Officer (the "Group CEO") as she is retiring to pursue her personal interests. Her last day of service will be 31 March 2024. She will relinquish all her appointments within the Group by her last day of service. Her resignation as Executive Director and the Group CEO has been accepted by the board of directors of the Company.
お知らせ • Jul 01Cordlife Group Limited Announces Change of Company SecretaryThe Board of Directors (the "Board") of Cordlife Group Limited announced the appointment of Ms. Low Mei Wan (Ms. Low) as Company Secretary of the company in place of Ms. Ang Siew Koon (Ms. Ang), with effect from 30 June 2023.
お知らせ • May 24Cordlife Group Limited Announces Resignation of Kuan Yoke Kay as the Joint Company SecretaryThe board of directors of Cordlife Group Limited announced the resignation of Ms. Kuan Yoke Kay (Ms. Kuan) as the joint company secretary with effect from 23 May 2023. Ms. Ang Siew Koon will remain the sole company secretary.
お知らせ • Jan 17Cordlife Group Limited Appoints that Hnin Yi as Group Chief Financial OfficerCordlife Group Limited appointed that Hnin Yi as Group Chief Financial Officer. Role And Responsibilities: Executive; Overall management of the Financials of the Group and help the Group achieve its objectives. Working Experience 1. Cordlife Group Limited (Jul 2010 to Jul 2013) - Financial Controller 2. Cordlife Group Limited (Aug 2013 to Jan 2017) - Chief Financial Officer 3. Cordlife Group Limited (Feb 2017 to Oct 2022) - Group Finance Director 4. Cordlife Group Limited (November 2022 to current) - Interim Group Chief Financial Officer. Professional Qualifications 1. Master of Business Administration - University of Manchester 2. Diploma in Accountancy - Ngee Ann Polytechnic.
